Item 8.01 Other Events.
On November 18, 2019, Karuna Therapeutics, Inc. (the "Company") announced
results from its Phase 2 clinical trial of KarXT for the treatment of acute
psychosis in patients with schizophrenia. A copy of this press release is
attached hereto as Exhibit 99.1 and is incorporated herein by reference. The
presentation containing the initial data from the Phase 2 clinical trial is
attached hereto as Exhibit 99.2 and is incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release issued by Karuna Therapeutics, Inc., dated November 18,
2019.
99.2 Company presentation, dated November 18, 2019.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses